Kimberly Brodovicz

Boehringer Ingelheim
Executive Director of Global Epidemiology
Kim Brodovicz is Executive Director, Late Stage Cardiometabolism Team Lead in Global Epidemiology and Real World Evidence at Boehringer Ingelheim. Kim has supported drugs and vaccines from early development to post-approval in a variety of therapeutic areas and has conducted numerous epidemiology studies using existing data and new data collection over her 20 years in industry. Prior to industry, Kim was an infectious disease epidemiologist at the Philadelphia Department of Public Health. Kim received her DrPH in epidemiology from the Johns Hopkins Bloomberg School of Public Health, a MPH in infectious disease epidemiology from Yale University School of Medicine, and BA in Medical Anthropology from the University of Pennsylvania.